GEOFFREY HENSON JOINS CALLISTO PHARMACEUTICALS

Callisto Pharmaceuticals Dec. 28 announced that, effective Jan. 1, 2007, Geoffrey Henson will become a consultant to the company. Henson has extensive experience in early stage clinical development of oncology drugs.

"The company will benefit immediately from Dr. Henson's expertise in oncology drug development and also his experience in previous clinical trials of Atiprimod," said Callisto CEO Gary Jacob. Geoff will be of great help to Callisto due to his knowledge of Atiprimod, as he is a co-discoverer of Atiprimod's potential in oncology."

Henson has been involved in drug discovery and development for over 20 years and has been a consultant to several biotechnology companies. He currently serves as CEO and a board member of FermaVir Pharmaceuticals.

Previously, Henson did extensive research in biochemistry and immunology and was a researcher and a member of the Basel Institute for Immunology in Basel, Switzerland.